Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03998566 · ClinicalTrials.gov registry record · NA
Radiopaque Hydrogel Spacer in Patients Undergoing Radiotherapy for Pancreatic Cancer
A NA study of Pancreatic Cancer, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 6
- Enrollment target
- 3
- Study locations
NCT03998566 is a NA study of Pancreatic Cancer that has completed, run by Boston Scientific Corporation. The registered enrollment target is 6 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03998566, a NA study of Pancreatic Cancer, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
- 3
- Study locations
Study Summary
An early feasibility study to evaluate feasibility, radiotherapy benefits and safety when using TraceIT tissue spacer to create space between pancreas and duodenum in patients with localized Pancreatic Cancer.
Conditions Studied
Interventions
- DEVICE TraceIT Tissue Spacer implantation
Study Locations (3)
Maryland
- Johns Hopkins Medicine - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-04-24 |
| Est. Completion | 2021-05-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03998566
The ClinicalTrials.gov registry entry for NCT03998566 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which TraceIT Tissue Spacer implantation is the first listed.
NCT03998566 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Maryland, Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT03998566 about?
NCT03998566 is a clinical study titled "Radiopaque Hydrogel Spacer in Patients Undergoing Radiotherapy for Pancreatic Cancer". An early feasibility study to evaluate feasibility, radiotherapy benefits and safety when using TraceIT tissue spacer to create space between pancreas and duodenum in patients with localized Pancreatic Cancer.
What is the current status of trial NCT03998566?
This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2019-04-24. Estimated completion is 2021-05-01.
What conditions does trial NCT03998566 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT03998566?
The interventions under investigation include: TraceIT Tissue Spacer implantation (DEVICE).
Who is sponsoring clinical trial NCT03998566?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03998566 being conducted?
This trial has 3 study locations across Maryland, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
RECRUITING · NA
-
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
RECRUITING · NA
-
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
RECRUITING · NA
-
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.